Recognition of Benztropine by the Dopamine Transporter (DAT) Differs from That of the Classical Dopamine Uptake Inhibitors Cocaine, Methylphenidate, and Mazindol as a Function of a DAT Transmembrane 1 Aspartic Acid Residue
Authors:
- Corry D. BondiCBCorry D. Bondi
- Amy Hauck NewmanANAmy Hauck Newman
- Santosh S. KulkarniSKSantosh S. Kulkarni
- Alan P. KozikowskiAKAlan P. Kozikowski
- Stephen PanSPStephen Pan
- Christopher K. SurrattCSChristopher K. Surratt
- 1 August 2005
- journal article
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 314 (2) , 575-583
Abstract
Binding of cocaine to the dopamine transporter (DAT) protein blocks synaptic dopamine clearance, triggering the psychoactive effects associated with the drug; the discrete drug-protein interactions, however, remain poorly understood. A longstanding postulate holds that cocaine inhibits DAT-mediated dopamine transport via competition with dopamine for formation of an ionic bond with the DAT transmembrane aspartic acid residue D79. In the present study, DAT mutations of this residue were generated and assayed for translocation of radiolabeled dopamine and binding of radiolabeled DAT inhibitors under identical conditions. When feasible, dopamine uptake inhibition potency and apparent binding affinity Ki values were determined for structurally diverse DAT inhibitors. The glutamic acid substitution mutant (D79E) displayed values indistinguishable from wild-type DAT in both assays for the charge-neutral cocaine analog 8-oxa-norcocaine, a finding not supportive of the D79 “salt bridge” ligand-docking model. In addressing whether the D79 side chain contributes to the DAT binding sites of other portions of the cocaine pharmacophore, only inhibitors with modifications of the tropane ring C-3 substituent, i.e., benztropine and its analogs, displayed a substantially altered dopamine uptake inhibition potency as a function of the D79E mutation. A single conservative amino acid substitution thus differentiated structural requirements for benztropine function relative to those for all other classical DAT inhibitors. Distinguishing the precise mechanism of action of this DAT inhibitor with relatively low abuse liability from that of cocaine may be attainable using DAT mutagenesis and other structure-function studies, opening the door to rational design of therapeutic agents for cocaine abuse.Keywords
This publication has 41 references indexed in Scilit:
- Identification of a Dopamine Transporter Ligand That Blocks the Stimulant Effects of CocaineJournal of Neuroscience, 2005
- Intracellular Domains of a Rat Brain GABA Transporter That Govern TransportJournal of Neuroscience, 2004
- Mutation of Trp84 and Asp313 of the dopamine transporter reveals similar mode of binding interaction for GBR12909 and benztropine as opposed to cocaineJournal of Neurochemistry, 2004
- The Human Dopamine Transporter Forms a Tetramer in the Plasma MembraneJournal of Biological Chemistry, 2003
- Oligomerization of serotonin transporter and its functional consequencesProceedings of the National Academy of Sciences, 2000
- Characterization of the interactions between the glycine transporters GLYT1 and GLYT2 and the SNARE protein syntaxin 1AFEBS Letters, 2000
- Transmembrane Domain I Contributes to the Permeation Pathway for Serotonin and Ions in the Serotonin TransporterThe Journal of Neuroscience, 1999
- Novel N-Substituted 3α-[Bis(4‘-fluorophenyl)methoxy]tropane Analogues: Selective Ligands for the Dopamine TransporterJournal of Medicinal Chemistry, 1997
- Dopamine transporter site-directed mutations differentially alter substrate transport and cocaine binding.Proceedings of the National Academy of Sciences, 1992
- Cocaine receptor: biochemical characterization and structure-activity relationships of cocaine analogs at the dopamine transporterJournal of Medicinal Chemistry, 1992